Vineet Laboratories Limited
BSE:543298 주식 보고서
Vineet Laboratories 과거 수익 실적 Vineet Laboratories의 수입은 연평균 -3.1%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 13.5%의 비율로 증가했습니다. 매출은 연평균 31.9%의 비율로 감소해 왔습니다. Vineet Laboratories의 자기자본이익률은 0.4%이고 순이익률은 0.1%입니다.
주요 정보 Pharmaceuticals 산업 성장 17.5% 매출 성장률 -31.9% 자기자본 수익률 0.4% 순이익 0.1% 다음 실적 업데이트 13 Nov 2024
최근 과거 실적 업데이트
Vineet Laboratories Limited to Report Q2, 2025 Results on Nov 13, 2024 Nov 06
First quarter 2025 earnings released: ₹2.31 loss per share (vs ₹1.36 loss in 1Q 2024) Aug 15
Vineet Laboratories Limited to Report Q1, 2025 Results on Aug 13, 2024 Jul 31
Full year 2024 earnings released: EPS: ₹1.11 (vs ₹1.36 in FY 2023) Jun 04
Vineet Laboratories Limited to Report Q4, 2024 Results on May 29, 2024 May 23
Third quarter 2024 earnings released: ₹2.22 loss per share (vs ₹1.51 profit in 3Q 2023) Feb 14
모든 업데이트 표시
Vineet Laboratories Limited to Report Q2, 2025 Results on Nov 13, 2024 Nov 06
Vineet Laboratories Limited, Annual General Meeting, Sep 27, 2024 Sep 04
First quarter 2025 earnings released: ₹2.31 loss per share (vs ₹1.36 loss in 1Q 2024) Aug 15
Vineet Laboratories Limited to Report Q1, 2025 Results on Aug 13, 2024 Jul 31
Investor sentiment improves as stock rises 20% Jul 30
Full year 2024 earnings released: EPS: ₹1.11 (vs ₹1.36 in FY 2023) Jun 04 Vineet Laboratories Limited Announces Resignation of Satish Pandurang Samant as Executive Director
New minor risk - Share price stability May 29
Vineet Laboratories Limited to Report Q4, 2024 Results on May 29, 2024 May 23
Investor sentiment improves as stock rises 15% Apr 03
Third quarter 2024 earnings released: ₹2.22 loss per share (vs ₹1.51 profit in 3Q 2023) Feb 14
Vineet Laboratories Limited to Report Q3, 2024 Results on Feb 12, 2024 Feb 03
Investor sentiment improves as stock rises 21% Dec 29
Investor sentiment improves as stock rises 32% Nov 17
Second quarter 2024 earnings released: EPS: ₹2.62 (vs ₹5.10 loss in 2Q 2023) Nov 11
Vineet Laboratories Limited Announces Appointment of Mr. Rameshkumar Bandari as Company Secretary and Compliance Officer Nov 11
Vineet Laboratories Limited to Report Q2, 2024 Results on Nov 10, 2023 Nov 04
Vineet Laboratories Limited Announces Resignation of Nirosha Ravikanti as Company Secretary / Compliance Officer of the Company Oct 29
New minor risk - Share price stability Oct 23
Vineet Laboratories Limited Appoints Mr. Satish Pandurang Samant as Chief Executive Officer Oct 18 Vineet Laboratories Limited Appoints Mr. Satish Pandurang Samant as Chief Executive Officer
Vineet Laboratories Limited, Annual General Meeting, Sep 28, 2023 Sep 06
Vineet Laboratories Limited Announces Board Changes Aug 13
New major risk - Revenue and earnings growth Aug 13
First quarter 2024 earnings released: ₹1.36 loss per share (vs ₹1.10 profit in 1Q 2023) Aug 13
Investor sentiment improves as stock rises 21% Aug 09
Vineet Laboratories Limited to Report Q1, 2024 Results on Aug 12, 2023 Aug 05
Full year 2023 earnings released: EPS: ₹1.36 (vs ₹7.20 in FY 2022) May 31
Vineet Laboratories Limited to Report Q4, 2023 Results on May 29, 2023 May 19
Investor sentiment improves as stock rises 24% Apr 06
MD & Director recently bought ₹333k worth of stock Apr 02
MD & Director recently bought ₹416k worth of stock Mar 30
MD & Director recently bought ₹868k worth of stock Mar 26
MD & Director recently bought ₹430k worth of stock Mar 16
Investor sentiment deteriorates as stock falls 16% Mar 08
Third quarter 2023 earnings released: EPS: ₹1.51 (vs ₹3.52 in 3Q 2022) Feb 16
Vineet Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023 Feb 07
Investor sentiment improved over the past week Dec 30
Second quarter 2023 earnings released: ₹5.10 loss per share (vs ₹3.52 profit in 2Q 2022) Nov 20
High number of new and inexperienced directors Nov 16
Vineet Laboratories Limited Approves Change the Designation of Kandula Murali Mohan from Non- Executive Director to Whole Time Director Oct 01
Vineet Laboratories Limited, Annual General Meeting, Sep 28, 2022 Sep 01
First quarter 2023 earnings released: EPS: ₹1.10 (vs ₹2.18 in 1Q 2022) Aug 02
Vineet Laboratories Limited Appoints Mrs. Yerukalapudi Hari Priya as Additional Independent Director (Non-Executive) Jul 30
Vineet Laboratories Limited to Report Q1, 2023 Results on Jul 29, 2022 Jul 22
Vineet Laboratories Limited Announces Resignation of Thotakura Uma Sangeetha as Independent Director Jun 07
Investor sentiment improved over the past week Jun 04
Vineet Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022 May 31
Full year 2022 earnings released: EPS: ₹7.16 (vs ₹1.93 in FY 2021) May 30
Vineet Laboratories Limited to Report Q4, 2022 Results on May 28, 2022 May 21
Investor sentiment improved over the past week May 18
High number of new and inexperienced directors Apr 27
Investor sentiment improved over the past week Apr 04
High number of new and inexperienced directors Mar 31
Investor sentiment deteriorated over the past week Feb 24
Vineet Laboratories 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역 BSE:543298 수익, 비용 및 수입 (INR Millions ) 날짜 수익 수익 G+A 비용 R&D 비용 30 Jun 24 1,369 1 65 0 31 Mar 24 1,510 10 65 0 31 Dec 23 1,707 27 62 0 30 Sep 23 2,049 61 64 0 30 Jun 23 2,010 -10 62 0 31 Mar 23 2,123 13 61 0 31 Dec 22 2,107 10 56 0 30 Sep 22 1,823 10 47 0 30 Jun 22 1,823 64 46 0 31 Mar 22 1,912 66 58 0 31 Mar 21 2,435 18 56 0
양질의 수익: 543298 은 높은 수익 을 보유하고 있습니다.
이익 마진 증가: 543298 는) 과거에 수익을 냈습니다.
과거 수익 성장 분석
수익추이: 543298 의 수입은 지난 5년 동안 매년 3.1% 씩 감소했습니다.
성장 가속화: 543298 지난해 흑자를 기록해 5년 평균과 비교하기 어려운 수익 성장률을 보이고 있습니다.
수익 대 산업: 543298 작년에 수익을 올렸기 때문에 지난 해 수익 성장을 Pharmaceuticals 업계( 18.7% )와 비교하기가 어렵습니다.
자기자본 수익률
높은 ROE: 543298 의 자본 수익률 ( 0.4% )은 낮음 으로 간주됩니다.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}